ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.
IPO Year: 2014
Exchange: NASDAQ
Website: contrafect.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2022 | $1.00 | Outperform → Mkt Perform | SVB Leerink |
| 7/14/2022 | $15.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 2/16/2022 | $14.00 → $9.00 | Outperform | SVB Leerink |
| 2/2/2022 | $6.50 | Speculative Buy → Buy | WBB Securities |
| 9/9/2021 | $14.00 | Outperform | SVB Leerink |
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is
Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company's chief financial officer effective August 31, 2021. "We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth," said John P. Furey, CEO of Imvax. "I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role i
YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Jane F. Barlow, MD, MPH, MBA to the Company’s board of directors (Board). “Dr. Barlow is an expert in both market access and payer reimbursement for the healthcare industry and, in particular, has extensive expertise in determining the economic impact and value of innovative, new modality therapies,” said Roger J. Pomerantz, M.D., President, Chief Executive Officer
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
4 - CONTRAFECT Corp (0001478069) (Issuer)
25-NSE - CONTRAFECT Corp (0001478069) (Subject)
8-K - CONTRAFECT Corp (0001478069) (Filer)
10-Q - CONTRAFECT Corp (0001478069) (Filer)
8-K - CONTRAFECT Corp (0001478069) (Filer)
424B3 - CONTRAFECT Corp (0001478069) (Filer)
EFFECT - CONTRAFECT Corp (0001478069) (Filer)
S-1 - CONTRAFECT Corp (0001478069) (Filer)
S-1 - CONTRAFECT Corp (0001478069) (Filer)
DEFA14A - CONTRAFECT Corp (0001478069) (Filer)
8-K - CONTRAFECT Corp (0001478069) (Filer)
SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00
Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously
SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously
WBB Securities upgraded ContraFect from Speculative Buy to Buy and set a new price target of $6.50
SVB Leerink initiated coverage of ContraFect with a rating of Outperform and set a new price target of $14.00
WBB Securities initiated coverage of ContraFect with a rating of Speculative Buy and set a new price target of $6.50
Chardan Capital reiterated coverage of ContraFect with a rating of Buy and set a new price target of $17.50 from $15.00 previously
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company's Interim Chief Medical Officer, will be presenting an updated overview of the Company's DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023. Dr. Nichols' presentation will discuss the upcoming IND submission for CF-370, our engineered lysin with significant activity against the mo
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the second quarter ended June 30, 2023. "We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter. If we are ultimately able to provide doctors and patients with a totally new treatment modality for infectio
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In consideration for the immediate exercise of the existing warrants for cash, the exercising holder received new unregistered warrants to
YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the presentation of data showing significant activity of its direct lytic agents against the most drug-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Klebsiella pneumoniae (K. pneumoniae) and Burkholderia spp, at ASM Microbe 2023 held from June 15-19, 2023 in Houston, Texas. "The data presented at ASM Microbe
YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023. The data being presented will feature CF-370 demonstrating efficacious activity in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Klebsiella pneumoniae (K. pneumon
YONKERS, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the first quarter ended March 31, 2023. "As a physician-scientist, I am truly excited to have begun dosing patients in our Phase 1b/2 clinical study of intra-articular exebacase for the treatment of chronic prosthetic joint infections of the knee. There has been no change in the standard of care for this
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS). "We are pleased by the